Ghiringhelli François, Bruchard Mélanie, Chalmin Fanny, Rébé Cédric
INSERM U866, Faculté de Médecine, Université de Bourgogne, Dijon, France.
J Biomed Biotechnol. 2012;2012:473712. doi: 10.1155/2012/473712. Epub 2012 Oct 14.
It is now well known that tumor immunosurveillance contributes to the control of cancer growth. Many mechanisms can be used by cancer cells to avoid the antitumor immune response. One such mechanism relies on the capacity of cancer cells or more generally of the tumor microenvironment to generate adenosine, a major molecule involved in antitumor T cell response suppression. Adenosine is generated by the dephosphorylation of extracellular ATP released by dying tumor cells. The conversion of ATP into adenosine is mediated by ectonucleotidase molecules, namely, CD73 and CD39. These molecules are frequently expressed in the tumor bed by a wide range of cells including tumor cells, regulatory T cells, Th17 cells, myeloid cells, and stromal cells. Recent evidence suggests that targeting adenosine by inhibiting ectonucleotidases may restore the resident antitumor immune response or enhance the efficacy of antitumor therapies. This paper will underline the impact of adenosine and ectonucleotidases on the antitumor response.
现在众所周知,肿瘤免疫监视有助于控制癌症生长。癌细胞可利用多种机制来逃避抗肿瘤免疫反应。其中一种机制依赖于癌细胞或更普遍地说肿瘤微环境产生腺苷的能力,腺苷是参与抑制抗肿瘤T细胞反应的主要分子。腺苷由垂死肿瘤细胞释放的细胞外ATP去磷酸化产生。ATP转化为腺苷由外核苷酸酶分子介导,即CD73和CD39。这些分子在肿瘤床中由多种细胞频繁表达,包括肿瘤细胞、调节性T细胞、Th17细胞、髓样细胞和基质细胞。最近的证据表明,通过抑制外核苷酸酶靶向腺苷可能恢复局部抗肿瘤免疫反应或增强抗肿瘤治疗的疗效。本文将强调腺苷和外核苷酸酶对抗肿瘤反应的影响。